Chronic chemotherapy-induced peripheral neuropathy and pain following paclitaxel versus docetaxel in breast cancer survivors: A cross-sectional study

IF 5.7 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Breast Pub Date : 2025-02-16 DOI:10.1016/j.breast.2025.104424

Nina Lykkegaard Gehr , Signe Timm , Kristine Bennedsgaard , Kasper Grosen , Erik Jakobsen , Anders Bonde Jensen , Jeanette Dupont Rønlev , Ann Søegaard Knoop , Nanna B. Finnerup , Lise Ventzel

{"title":"Chronic chemotherapy-induced peripheral neuropathy and pain following paclitaxel versus docetaxel in breast cancer survivors: A cross-sectional study","authors":"Nina Lykkegaard Gehr , Signe Timm , Kristine Bennedsgaard , Kasper Grosen , Erik Jakobsen , Anders Bonde Jensen , Jeanette Dupont Rønlev , Ann Søegaard Knoop , Nanna B. Finnerup , Lise Ventzel","doi":"10.1016/j.breast.2025.104424","DOIUrl":null,"url":null,"abstract":"<div><div>Chemotherapy-induced peripheral neuropathy (CIPN) is a concerning late effect of taxane treatment. This study aimed to explore and compare long-term symptoms and consequences of CIPN after docetaxel and paclitaxel treatment.</div><div>Patients with breast cancer who had followed Danish recommended adjuvant docetaxel or paclitaxel treatment regimens completed an online questionnaire 2–3 years after treatment. The questionnaire comprised the Michigan Neuropathy Screen Instrument, the European Organization for Research and Treatment of Cancer (EORTC) QLQ-CIPN20, EORTC QLQ C30, and CIPN-specific symptoms. Painful CIPN was assessed using the Douleur Neuropathique 4 Questions.</div><div>Questionnaires from 411 patients (docetaxel: 192, paclitaxel: 219) were analyzed. No significant difference in the prevalence of possible CIPN between the two groups was observed (docetaxel: 48.4 % [93/192] vs. paclitaxel: 45.2 % [99/219]; 95 % CI: 6.4 - 12.9, p = 0.51). However, the EORTC-QLQ-CIPN20 sum score was higher in the docetaxel group (difference: 3.0; 95 % CI: 0.0–6.1, p = 0.05).</div><div>Among patients with reported CIPN symptoms, significantly more in the docetaxel group reported painful CIPN (docetaxel: 53.8 % [50/93] than in the paclitaxel group: 34.3 % [34/99]; p = 0.01). Quality of life scores from the EORCT-QLQ-C30 questionnaire were significantly lower in those with possible CIPN than in those without and lower in patients with painful possible CIPN than in those with painless CIPN.</div><div>Docetaxel caused more severe and painful CIPN symptoms than paclitaxel. These findings are highly relevant, as docetaxel remains a crucial component of cancer treatments.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 104424"},"PeriodicalIF":5.7000,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960977625000438","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a concerning late effect of taxane treatment. This study aimed to explore and compare long-term symptoms and consequences of CIPN after docetaxel and paclitaxel treatment.

Patients with breast cancer who had followed Danish recommended adjuvant docetaxel or paclitaxel treatment regimens completed an online questionnaire 2–3 years after treatment. The questionnaire comprised the Michigan Neuropathy Screen Instrument, the European Organization for Research and Treatment of Cancer (EORTC) QLQ-CIPN20, EORTC QLQ C30, and CIPN-specific symptoms. Painful CIPN was assessed using the Douleur Neuropathique 4 Questions.

Questionnaires from 411 patients (docetaxel: 192, paclitaxel: 219) were analyzed. No significant difference in the prevalence of possible CIPN between the two groups was observed (docetaxel: 48.4 % [93/192] vs. paclitaxel: 45.2 % [99/219]; 95 % CI: 6.4 - 12.9, p = 0.51). However, the EORTC-QLQ-CIPN20 sum score was higher in the docetaxel group (difference: 3.0; 95 % CI: 0.0–6.1, p = 0.05).

Among patients with reported CIPN symptoms, significantly more in the docetaxel group reported painful CIPN (docetaxel: 53.8 % [50/93] than in the paclitaxel group: 34.3 % [34/99]; p = 0.01). Quality of life scores from the EORCT-QLQ-C30 questionnaire were significantly lower in those with possible CIPN than in those without and lower in patients with painful possible CIPN than in those with painless CIPN.

Docetaxel caused more severe and painful CIPN symptoms than paclitaxel. These findings are highly relevant, as docetaxel remains a crucial component of cancer treatments.

查看原文本刊更多论文

乳腺癌幸存者紫杉醇与多西紫杉醇治疗后慢性化疗诱导的周围神经病变和疼痛：一项横断面研究

化疗引起的周围神经病变（CIPN）是紫杉烷治疗的晚期效应。本研究旨在探讨和比较多西紫杉醇和紫杉醇治疗后CIPN的长期症状和后果。接受丹麦推荐的辅助多西紫杉醇或紫杉醇治疗方案的乳腺癌患者在治疗后2-3年完成了一份在线问卷。问卷包括密歇根神经病变筛查仪、欧洲癌症研究与治疗组织（EORTC） QLQ- cipn20、EORTC QLQ C30和cipn特异性症状。疼痛性CIPN采用双重神经病4题进行评估。对411例患者（多西紫杉醇192例，紫杉醇219例）的问卷进行分析。两组间可能发生CIPN的发生率无显著差异(多西紫杉醇：48.4% [93/192]vs紫杉醇：45.2% [99/219]；95% CI: 6.4 - 12.9, p = 0.51)。但多西紫杉醇组EORTC-QLQ-CIPN20总分较高(差异：3.0；95% CI: 0.0-6.1, p = 0.05)。在报告CIPN症状的患者中，多西紫杉醇组报告疼痛性CIPN的患者明显多于多西紫杉醇组（多西紫杉醇组：53.8% [50/93]）：34.3% [34/99]；p = 0.01)。在EORCT-QLQ-C30问卷调查中，有可能发生CIPN的患者的生活质量得分明显低于无可能发生CIPN的患者，有可能发生疼痛性CIPN的患者的生活质量得分明显低于无可能发生CIPN的患者。多西紫杉醇引起的CIPN症状比紫杉醇更严重、更痛苦。这些发现是高度相关的，因为多西紫杉醇仍然是癌症治疗的关键组成部分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast 医学-妇产科学

CiteScore

8.70

自引率

2.60%

发文量

165

审稿时长

59 days

期刊介绍： The Breast is an international, multidisciplinary journal for researchers and clinicians, which focuses on translational and clinical research for the advancement of breast cancer prevention, diagnosis and treatment of all stages.